<DOC>
	<DOC>NCT02456480</DOC>
	<brief_summary>To assess the pharmacodynamics, safety/tolerability, and efficacy of omiganan in patients with mild to moderate atopic dermatitis (AD).</brief_summary>
	<brief_title>Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>1. Male and female subjects with mild to moderate AD 18 to 65 years of age, inclusive. 2. AD diagnosed by physician / medical specialist and that has been (intermittently) present for at least 1 year 3. Able to participate and willing to give written informed consent and to comply with the study restrictions. 1. Have any current and / or recurrent clinically significant skin condition in the treatment area other than AD. 2. Any confirmed, active significant allergic reactions (urticaria or anaphylaxis) including allergic reactions against any drug, multiple drug allergies or (ingredients of) emollients. 3. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>